This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study to Assess the Long-term Performance of SmartSet® HV and SmartSet® GHV Bone Cements in Primary Total Hip Replacement

This study has been completed.
Information provided by (Responsible Party):
DePuy International Identifier:
First received: March 19, 2009
Last updated: March 2, 2017
Last verified: March 2017
The purpose of this study is to monitor the performance of artificial hip joints implanted with two different bone cements, SmartSet® HV and SmartSet® GHV, in the treatment of patients with hip joint disease requiring a total hip replacement. Patients who enter the study will be randomly allocated to SmartSet® HV or SmartSet® GHV and will be evaluated at regular intervals following hip surgery using patient, clinical and x-ray assessments

Condition Intervention Phase
Rheumatoid Arthritis Osteoarthritis Post-traumatic Arthritis Collagen Disorders Avascular Necrosis Traumatic Femoral Fractures Nonunion of Femoral Fractures Congenital Hip Dysplasia Slipped Capital Femoral Epiphysis Device: SmartSet® HV bone cement Device: SmartSet® GHV bone cement Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomised, Uncontrolled, Single-Centre, Post-Market Surveillance Study To Evaluate The Performance Of SmartSet® HV and SmartSet® GHV Bone Cements In Primary Cemented Total Hip Arthroplasty(THA)

Resource links provided by NLM:

Further study details as provided by DePuy International:

Primary Outcome Measures:
  • Kaplan-Meier survivorship [ Time Frame: Annually ]

Secondary Outcome Measures:
  • Harris Hip Score [ Time Frame: Annually ]
  • Oxford Hip Score [ Time Frame: Annually ]
  • Radiological Analysis [ Time Frame: Annually ]

Enrollment: 243
Study Start Date: March 2006
Study Completion Date: July 2016
Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1) SmartSet® HV Bone Cement
A high viscosity bone cement for use in total hip replacement (without gentamicin)
Device: SmartSet® HV bone cement
A high viscosity bone cement for use in total hip replacement (without gentamicin)
Active Comparator: 2) SmartSet® GHV Bone Cement
A high viscosity bone cement for use in total hip replacement (with gentamicin)
Device: SmartSet® GHV bone cement
A high viscosity bone cement for use in total hip replacement (with gentamicin)


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

i) Male or female subjects, aged between 18 and 75 years (inclusive).

ii) Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.

iii) Subjects who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.

iv) Subjects requiring primary total hip arthroplasty and are considered suitable for a cemented femoral component.

Exclusion Criteria:

i) Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.

ii) Women who are pregnant.

iii) Subjects who are known drug or alcohol abusers or with psychological disorders that could effect follow-up care or treatment outcomes.

iv) Subjects who have participated in a clinical study with an investigational product in the last 6 month(s).

v) Subjects who are currently involved in any injury litigation claims.

vi) Subjects with contraindications normally applicable to the use of conventional bone cement, in accordance with the manufacturer's Instructions For Use.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00872066

Orthopaedic-traumatology Clinic University Hospital Martin
Martin, Slovakia
Sponsors and Collaborators
DePuy International
Principal Investigator: Libor Nečas, M.D. Orthopaedic-truamatology Clinic, University Hospital Martin, Slovakia
  More Information

Responsible Party: DePuy International Identifier: NCT00872066     History of Changes
Other Study ID Numbers: CT02/11
Study First Received: March 19, 2009
Last Updated: March 2, 2017

Keywords provided by DePuy International:
Bone Cement

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Fractures, Bone
Femoral Fractures
Hip Dislocation
Hip Dislocation, Congenital
Slipped Capital Femoral Epiphyses
Collagen Diseases
Rheumatic Diseases
Joint Diseases
Musculoskeletal Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Wounds and Injuries
Pathologic Processes
Leg Injuries
Hip Injuries
Musculoskeletal Abnormalities
Congenital Abnormalities
Bone Diseases, Developmental
Bone Diseases
Epiphyses, Slipped
Anti-Bacterial Agents
Anti-Infective Agents processed this record on September 21, 2017